Clinical trial
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant
NCT02781571 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 27, 2016
- Completion date
- July 28, 2017
- Enrollment
- 79 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
hepatitis c virus infection